

Practitioner's Docket No. 81669

CHAPTER II

Preliminary Classification:

Proposed Class:

Subclass:

NOTE: "All applicants are requested to include a preliminary classification on newly filed patent applications. The preliminary classification, preferably class and subclass designations, should be identified in the upper right-hand corner of the letter of transmittal accompanying the application papers, for example 'Proposed Class 2, subclass 129.'" M.P.E.P., § 601, 7th ed.

TRANSMITTAL LETTER
TO THE UNITED STATES ELECTED OFFICE (EO/US)

(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

PCT/DE99/03747 19 NOVEMBER 1999 19 NOVEMBER 1998
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

METHOD FOR THE IDENTIFICATION OF CYTOSINE METHYLATION
TITLE OF INVENTION

PATTERNS IN GENOMIC DNA

APPLICANT(S)

KATHRIN BERLIN (APPLICANT)

Box PCT

Assistant Commissioner for Patents

Washington D.C. 20231

ATTENTION: EO/US

CERTIFICATION UNDER 37 C.F.R. § 1.10*


(Express Mail label number is mandatory.)

(Express Mail certification is optional.)

I hereby certify that this Transmittal Letter and the papers indicated as being transmitted therewith is being deposited with the United States Postal Service on this date May 18, 2001, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL826369143US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

EDWARD M. KRIEGSMAN

(type or print name of person mailing paper)



Signature of person mailing paper

WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. § 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. § 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Transmittal Letter to the United States Elected Office (EO/US) [13-18]—page 1 of 8)

095633-082901

NOTE: To avoid abandonment of the application, the applicant shall furnish to the USPTO, not later than 20 months from the priority date: (1) a copy of the international application, unless it has been previously communicated by the International Bureau or unless it was originally filed in the USPTO; and (2) the basic national fee (see 37 C.F.R. § 1.492(a)). The 30-month time limit may not be extended. 37 C.F.R. § 1.495.

WARNING: Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. § 1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing—See 37 C.F.R. § 1.8.

NOTE: Documents and fees must be clearly identified as a submission to enter the national state under 35 U.S.C. § 371 otherwise the submission will be considered as being made under 35 U.S.C. § 111. 37 C.F.R. § 1.494(f).

- I. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. § 371:
- ☒ This express request to immediately begin national examination procedures (35 U.S.C. § 371(f)).
 - ☒ The U.S. National Fee (35 U.S.C. § 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

09856333

09/856533

JC18 Rec'd PCT/PTO 1 8 MAY 2001

2. Fees

CLAIMS FEE	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
<input checked="" type="checkbox"/>	TOTAL CLAIMS	53 - 20 =	33	× \$18.00 =	\$ 594
	INDEPENDENT CLAIMS	1 - 3 =	0	\$ 80 × \$78.00 =	0
	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$260.00 \$270				\$270
BASIC FEE**	<input type="checkbox"/> U.S. PTO WAS INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where an International preliminary examination fee as set forth in § 1.482 has been paid on the international application to the U.S. PTO: <input type="checkbox"/> and the international preliminary examination report states that the criteria of novelty, inventive step (non-obviousness) and industrial activity, as defined in PCT Article 33(1) to (4) have been satisfied for all the claims presented in the application entering the national stage (37 C.F.R. § 1.492(a)(4)) \$96.00 <input type="checkbox"/> and the above requirements are not met (37 C.F.R. § 1.492(a)(1)) \$670.00 <input checked="" type="checkbox"/> U.S. PTO WAS NOT INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where no international preliminary examination fee as set forth in § 1.482 has been paid to the U.S. PTO, and payment of an international search fee as set forth in § 1.445(a)(2) to the U.S. PTO: <input type="checkbox"/> has been paid (37 C.F.R. § 1.492(a)(2)) \$690.00 <input type="checkbox"/> has not been paid (37 C.F.R. § 1.492(a)(3)) \$970.00 <input checked="" type="checkbox"/> where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 C.F.R. § 1.492(a)(5)) \$825.00 \$860				\$860
	Total of above Calculations				= \$1724
SMALL ENTITY	Reduction by 1/2 for filing by small entity, if applicable. Affidavit must be filed also. (note 37 C.F.R. § 1.9, 1.27, 1.28)				- \$862
	Subtotal				\$862
	Total National Fee				\$862
	Fee for recording the enclosed assignment document \$40.00 (37 C.F.R. § 1.21(h)). (See Item 13 below). See attached "ASSIGNMENT COVER SHEET".				0
TOTAL	Total Fees enclosed				\$862

T 0 6 2 3 0 " E E 9 5 8 6 0

Applicant
is a small
entity

*See attached Preliminary Amendment Reducing the Number of Claims.

- i. ☒ A check in the amount of \$862 to cover the above fees is enclosed.
- ii. ☐ Please charge Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.

****WARNING:** "To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date: * * * (2) the basic national fee (see § 1.492(a)). The 30-month time limit may not be extended." 37 C.F.R. § 1.495(b).

WARNING: If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office. 37 C.F.R. § 1.495(b)(2). The payment of the surcharge set forth in § 1.492(e) is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than thirty (30) months after the priority date. Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.136 apply to the period which is set. Notice of Jan. 3, 1993, 1147 O.G. 29 to 40.

3. ☒ A copy of the International application as filed (35 U.S.C. § 371(c)(2)):

NOTE: Section 1.495 (b) was amended to require that the basic national fee and a copy of the international application must be filed with the Office by 30 months from the priority date to avoid abandonment. "The International Bureau normally provides the copy of the international application to the Office in accordance with PCT Article 20. At the same time, the International Bureau notifies applicant of the communication to the Office. In accordance with PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence that the communication has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant normally need only check to be sure the notice from the International Bureau has been received and then pay the basic national fee by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See item 14c below.

- a. ☒ is transmitted herewith.
- b. ☐ is not required, as the application was filed with the United States Receiving Office.
- c. ☐ has been transmitted
 - i. ☐ by the International Bureau.
Date of mailing of the application (from form PCT/1B/308): _____
 - ii. ☐ by applicant on _____
Date

4. ☒ A translation of the International application into the English language (35 U.S.C. § 371(c)(2)):

- a. ☒ is transmitted herewith.
- b. ☐ is not required as the application was filed in English.
- c. ☐ was previously transmitted by applicant on _____
Date
- d. ☐ will follow.

F06230" EEE9960

5. ☐ Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. § 371(c)(3)):

NOTE: The Notice of January 7, 1993 points out that 37 C.F.R. § 1.495(a) was amended to clarify the existing and continuing practice that PCT Article 19 amendments must be submitted by 30 months from the priority date and this deadline may not be extended. The Notice further advises that: "The failure to do so will not result in loss of the subject matter of the PCT Article 19 amendments. Applicant may submit that subject matter in a preliminary amendment filed under section 1.121. In many cases, filing an amendment under section 1.121 is preferable since grammatical or idiomatic errors may be corrected." 1147 O.G. 29-40, at 36.

- a. ☐ are transmitted herewith.
 - b. ☐ have been transmitted
 - i. ☐ by the International Bureau.
Date of mailing of the amendment (from form PCT/1B/308): _____
 - ii. ☐ by applicant on (date) _____.
Date
 - c. ☐ have not been transmitted as
 - i. ☐ applicant chose not to make amendments under PCT Article 19.
Date of mailing of Search Report (from form PCT/ISA/210): _____
 - ii. ☐ the time limit for the submission of amendments has not yet expired.
The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.
6. ☐ A translation of the amendments to the claims under PCT Article 19 (38 U.S.C. § 371(c)(3)):
- a. ☐ is transmitted herewith.
 - b. ☐ is not required as the amendments were made in the English language.
 - c. ☐ has not been transmitted for reasons indicated at point 5(c) above.
7. ☒ A copy of the international examination report (PCT/IPEA/409)
- ☒ is transmitted herewith.
 - ☐ is not required as the application was filed with the United States Receiving Office.
8. ☐ Annex(es) to the international preliminary examination report
- a. ☐ is/are transmitted herewith.
 - b. ☐ is/are not required as the application was filed with the United States Receiving Office.
9. ☐ A translation of the annexes to the international preliminary examination report
- a. ☐ is transmitted herewith.
 - b. ☐ is not required as the annexes are in the English language.

10. ☒ An oath or declaration of the inventor (35 U.S.C. § 371(c)(4)) complying with 35 U.S.C. § 115

a. ☐ was previously submitted by applicant on _____
Date

b. ☐ is submitted herewith, and such oath or declaration

i. ☐ is attached to the application.

ii. ☐ identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. § 1.70.

c. ☒ will follow.

II. Other document(s) or information included:

11. ☒ An International Search Report (PCT/ISA/210) or Declaration under PCT Article 17(2)(a):

a. ☒ is transmitted herewith.

b. ☐ has been transmitted by the International Bureau.
Date of mailing (from form PCT/IB/308): _____

c. ☐ is not required, as the application was searched by the United States International Searching Authority.

d. ☐ will be transmitted promptly upon request.

e. ☐ has been submitted by applicant on _____
Date

12. ☐ An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98:

a. ☐ is transmitted herewith.

Also transmitted herewith is/are:

☐ Form PTO-1449 (PTO/SB/08A and 08B).

☐ Copies of citations listed.

b. ☐ will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. § 371(c).

c. ☐ was previously submitted by applicant on _____
Date

13. ☐ An assignment document is transmitted herewith for recording.

A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.

09/856333 092304

14. ☒ Additional documents:
- a. ☐ Copy of request (PCT/RO/101)
 - b. ☐ International Publication No. _____
 - i. ☐ Specification, claims and drawing
 - ii. ☐ Front page only
 - c. ☒ Preliminary amendment (37 C.F.R. § 1.121)
 - d. ☐ Other

15. ☒ The above checked items are being transmitted
- a. ☒ before 30 months from any claimed priority date.
 - b. ☐ after 30 months.

16. ☐ Certain requirements under 35 U.S.C. § 371 were previously submitted by the applicant on _____, namely:

AUTHORIZATION TO CHARGE ADDITIONAL FEES

WARNING: Accurately count claims, especially multiple dependant claims, to avoid unexpected high charges if extra claims are authorized.

NOTE: "A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).

NOTE: "Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.26(a).

- ☒ The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. 11-1755

☒ 37 C.F.R. § 1.492(a)(1), (2), (3), and (4) (filing fees)

WARNING: Because failure to pay the national fee within 30 months without extension (37 C.F.R. § 1.495(b)(2)) results in abandonment of the application, it would be best to always check the above box.

(Transmittal Letter to the United States Elected Office (EO/US) [13-18]—page 7 of 8)

09856333 00000000

JUL 13 2001

- ☐ 37 C.F.R. § 1.492(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.492(d)), it might be best not to authorize the PTO to charge additional claim fees, except possible when dealing with amendments after final action.

- ☐ 37 C.F.R. § 1.17 (application processing fees)
- ☐ 37 C.F.R. § 1.17(a)(1)-(5) (extension fees pursuant to § 1.136(a).
- ☐ 37 C.F.R. § 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. § 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R. § 1.311(b).

NOTE: 37 C.F.R. § 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying . . . issue fee." From the wording of 37 C.F.R. § 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

- ☐ 37 C.F.R. § 1.492(e) and (f) (surcharge fees for filing the declaration and/or filing an English translation of an International Application later than 30 months after the priority date).



SIGNATURE OF PRACTITIONER

EDWARD M. KRIEGSMAN

(type or print name of practitioner)

KRIEGSMAN & KRIEGSMAN

665 FRANKLIN STREET

P.O. Address

FRAMINGHAM, MA 01702

Reg. No.: 33,529

Tel. No.: (508) 879-3500

Customer No.: 23685

FOR "ELECTED" OFFICE

PATENT
Attorney Docket No. 81669

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
KATHRIN BERLIN)	
)	
Serial No.: Unassigned)	Group Art Unit: Unknown
)	
Filed: Herewith)	Examiner: Unknown
)	
For: METHOD FOR THE)	
IDENTIFICATION OF CYTOSINE)	
METHYLATION PATTERNS IN)	
GENOMIC DNA)	

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Preliminary to examination of the subject application, please enter the amendment below.

IN THE CLAIMS:

Please amend claims 3-6, 9-11, 15, 18-21 and 25-27 as follows:

3. (Amended) Method according to claim 1, further characterized in that disulfite (bisulfite, pyrosulfite) is utilized as the reagent for selective conversion of cytosine to uracil, whereby 5-methylcytosine remains unchanged, in step a) according to claim 1.

4. (Amended) Method according to claim 1, further characterized in that genomic DNA of several individuals, tissues, cell lines or cells is amplified jointly in step b) of claim 1.

5. (Amended) Method according to claim 1, further characterized in that genomic DNA of several individuals, tissues, cell lines or cells is amplified separately and then treated jointly according to step e) of claim 1.

6. (Amended) Method according to claim 1, further characterized in that by formation of heteroduplexes from the DNA of different individuals, tissues, cell lines or cells, erroneous base pairings are produced at the positions at which a 5-methylcytosine was localized in the genomic DNA.

9. (Amended) Method according to claim 6, further characterized in that the erroneous base pairings by means of "chemical mismatch cleavage" (chemical modification at non-complementary positions) lead to a specific or sufficiently selective backbone cleavage at these positions.

10. (Amended) Method according to claim 6, further characterized in that the DNA is cleaved enzymatically specifically or sufficiently selectively at the erroneous base pairings.

11. (Amended) Method according to claim 1, further characterized in that DNA fragments are obtained in step e) according to claim 1, whose size infers the cleavage positions and thus the position of methylcytosines and/or the methylation positions that differ between different individuals, tissues, cell lines or cells.

15. (Amended) Method according to claim 13, further characterized in that the size of the fragments produced in step e) according to claim 1 is adapted to the performance capacity of the mass spectrometer.

18. (Amended) Method according to claim 1, further characterized in that in step b) one primer of the PCR is provided with a chemical function, so that the PCR product can be immobilized on a surface.

19. (Amended) Method according to claim 1, further characterized in that the PCR product produced in step b) is transferred to different reaction vessels and the surfaces of the reaction vessels are chemically treated such that the PCR product can be bound thereon.

20. (Amended) Method according to claim 1, further characterized in that PCR products of different individuals that are produced in step c) are transferred into different reaction vessels the surfaces of which are chemically treated such that the PCR product can be bound thereon.

21. (Amended) Method according to claim 1, further characterized in that an enzyme which forms a complex with a non-complementary base pair is used for step e).

25. (Amended) Method according to claim 1, further characterized in that one compares an amplified DNA sample according to step c) in claim 1, which displays a difference relative to an amplified DNA sample in step b), in a second run of the method itself, with a similar DNA sample according to step b) in claim 1 and with all other DNA samples to be investigated.

26. (Amended) Method according to claim 1, further characterized in that a preselection of gene segments to be investigated in detail by the mass spectrometer is conducted by means of fluorescence labeling or chemiluminescence labeling of the immobilized DNA strand, the lack of which, after conducting steps d) and e) of claim 1 and a washing step, indicates the presence of methylated cytosines in the investigated genomic DNA segment.

27. (Amended) Method according to one of claims 1 to 25, further characterized in that a preselection is made of the gene segments to be investigated in detail by mass spectrometry by means of a more non-specific variant.


REMARKS

No claims have been canceled or added. Claims 3-6, 9-11, 15, 18-21 and 25-27 have been amended. Therefore, claims 1-29 are under active consideration.

If there are any fees due in connection with the filing of this paper that are not accounted for, the Examiner is authorized to charge the fees to our Deposit Account No. 11-1755. If a fee is required for an extension of time under 37 C.F.R. 1.136 that is not accounted for already, such an extension of time is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Kriegsman & Kriegsman

By: 

Edward M. Kriegsman
Reg. No. 33,529
665 Franklin Street
Framingham, MA 01702
(508) 879-3500

Dated: May 18, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on _____.

Edward M. Kriegsman
Reg. No. 33,529
Dated: _____

MARKED-UP AMENDED CLAIMS 3-6, 9-11, 15, 18-21 AND 25-27

3. (Amended) Method according to [claims] claim 1 [to 2], further characterized in that disulfite (bisulfite, pyrosulfite) is utilized as the reagent for selective conversion of cytosine to uracil, whereby 5-methylcytosine remains unchanged, in step a) according to claim 1.

4. (Amended) Method according to [one of claims] claim 1 [to 3], further characterized in that genomic DNA of several individuals, tissues, cell lines or cells is amplified jointly in step b) of claim 1.

5. (Amended) Method according to [one of claims] claim 1 [to 3], further characterized in that genomic DNA of several individuals, tissues, cell lines or cells is amplified separately and then treated jointly according to step e) of claim 1.

6. (Amended) Method according to [one of claims] claim 1 [to 5], further characterized in that by formation of heteroduplexes from the DNA of different individuals, tissues, cell lines or cells, erroneous base pairings are produced at the positions at which a 5-methylcytosine was localized in the genomic DNA.

9. (Amended) Method according to [one of claims] claim 6 [to 8], further characterized in that the erroneous base pairings by means of “chemical mismatch cleavage” (chemical modification at non-complementary positions) lead to a specific or sufficiently selective backbone cleavage at these positions.

10. (Amended) Method according to [one of claims] claim 6 [to 8], further characterized in that the DNA is cleaved enzymatically specifically or sufficiently selectively at the erroneous base pairings.

11. (Amended) Method according to [one of claims] claim 1 [to 10], further characterized in that DNA fragments are obtained in step e) according to claim 1, whose size infers the cleavage positions and thus the position of methylcytosines and/or the methylation positions that differ between different individuals, tissues, cell lines or cells.

15. (Amended) Method according to [claims] claim 13 [or 14], further characterized in that the size of the fragments produced in step e) according to claim 1 is adapted to the performance capacity of the mass spectrometer.

18. (Amended) Method according to [one of claims] claim 1 [or 2], further characterized in that in step b) one primer of the PCR is provided with a chemical function, so that the PCR product can be immobilized on a surface.

19. (Amended) Method according to [one of claims] claim 1 [or 2], further characterized in that the PCR product produced in step b) is transferred to different reaction vessels and the surfaces of the reaction vessels are chemically treated such that the PCR product can be bound thereon.

20. (Amended) Method according to [one of claims] claim 1 [or 2], further characterized in that PCR products of different individuals that are produced in step c) are transferred into different reaction vessels [prepared according to claim 19] the surfaces of which are chemically treated such that the PCR product can be bound thereon.

21. (Amended) Method according to [one of claims] claim 1 [or 2], further characterized in that an enzyme which forms a complex with a non-complementary base pair is used for step e).

25. (Amended) Method according to [one of claims] claim 1 [to 24], further characterized in that one compares an amplified DNA sample according to step c) in claim 1, which displays a difference relative to an amplified DNA sample in step b), in a second run of the method itself, with

a similar DNA sample according to step b) in claim 1 and with all other DNA samples to be investigated.

26. (Amended) Method according to [one of claims] claim 1 [to 25], further characterized in that a preselection of gene segments to be investigated in detail by the mass spectrometer is conducted by means of fluorescence labeling or chemiluminescence labeling of the immobilized DNA strand, the lack of which, after conducting steps d) and e) of claim 1 and a washing step, indicates the presence of methylated cytosines in the investigated genomic DNA segment.

27. (Amended) Method according to one of claims 1 to 25, further characterized in that a preselection is made of the gene segments to be investigated in detail by mass spectrometry by means of a more non-specific variant [according to claims 20-23].

METHOD FOR THE IDENTIFICATION OF CYTOSINE METHYLATION PATTERNS IN GENOMIC DNA

The invention concerns a method for the identification of 5-methylcytosine positions in genomic DNA.

The genetic information, which is obtained as a base sequence by complete sequencing of genomic DNA, only incompletely describes the genome of a cell. 5-Methylcytosine nucleobases, which are formed in the cell by reversible methylation of DNA, are an epigenetic information carrier and serve, for example, for the regulation of promoters. The methylation state of a genome represents the present status of gene expression, similar to an mRNA expression pattern.

5-Methylcytosine is the most frequent covalently modified base in the DNA of eukaryotic cells. It plays a role, for example, in the regulation of transcription, genomic imprinting and in tumorigenesis. The identification of 5-methylcytosine as a component of genetic information is thus of considerable interest. 5-Methylcytosine positions, however, cannot be identified by sequencing, since 5-methylcytosine has the same base pairing behavior as cytosine. Unfortunately, the epigenetic information that is carried by 5-methylcytosines becomes completely lost in PCR [polymerase chain reaction] amplification, and there is no method for obtaining this information by an amplification step.

Several methods are known, which solve these problems. For the most part, a chemical reaction or enzymatic treatment of the genomic DNA is

TOE230"EE95360

conducted, as a consequence of which, cytosine nucleobases can be distinguished from methylcytosine nucleobases. One current method is the reaction of genomic DNA with disulfite (also denoted bisulfite or pyrosulfite), which leads to the conversion of cytosine bases to uracil in two steps after alkaline hydrolysis (Shapiro, R., Cohen, B, Servis, R. Nature 227, 1047 (1970). 5-Methylcytosine remains unchanged under these conditions. The conversion of C to U leads to a change in the base sequence, from which the original 5-methylcytosines can now be determined by sequencing (only these [bases] will still supply a band in the C lane).

An overview of the other known possibilities for detecting 5-methylcytosines can be derived from the following review article together with the references belonging thereto: Rein, T., DePamphilis, M.L., Zorbas, H., Nucleic Acids Res. 26, 2255 (1998).

A method for characterizing specific DNA sequences is described in DD 293,139 A5, in which the DNA molecules, whose unmethylated recognition sites can be cleaved by an appropriate restriction endonuclease, are incubated in a reaction mixture with a second, unmethylated DNA species (particularly oligonucleotide duplexes, which contain the recognition site).

WO 97/46,705 A1 discloses a method for the detection of a methylated nucleic acid containing CpG, whereby the sample containing nucleic acid is brought into contact with a reagent, which modifies unmethylated cytosine, so that nucleic acids containing CpG in the sample are amplified by means of CpG-specific oligonucleotide primers, whereby the oligonucleotide primer

differentiates between modified methylated and unmethylated nucleic acids and detects methylated nucleic acids.

In addition, US 5,824,471 A1 describes a method for the determination of deviations between two nucleic acid strands, whereby a multiple number of duplexes are formed from the two strands or parts thereof and these duplexes are contacted with a first and a second different bacteriophage resolvase and whereby it is then established from which bacteriophage resolvase the duplex is cleaved, whereupon the differences are determined thereby.

However, it is not always necessary to actually determine the entire sequence of a gene or gene segment, as is the objective in the case of sequencing. This is particularly true if only a few 5-methylcytosine positions are to be found within a long base sequence in the case of a multiple number of different samples. Here, sequencing supplies essentially redundant information and is also very expensive. This is also true in the case when the sequence is already known and only the methylation positions need to be shown. It is also conceivable that in several cases in general, only the differences in the methylation pattern between different genomic DNA samples are of interest and that the determination of a multiple number of corresponding methylated positions as well as sequencing can be dispensed with. For the questions posed here, up until now, there has existed no method which supplies the desired result in a cost-favorable manner without sequencing each individual sample.

The sequence information per se is also continually less novel, since genome projects, whose goal is the complete sequence of various organisms,

are swiftly advancing. In fact, currently, even though only approximately 5% of the human genome has been completely sequenced, the study is progressing rapidly, since other genome projects have been completed and in this way sequencing resources have been freed up, so that every year another 5% is added. It is calculated that the sequencing of the human genome will be completed by the year 2006.

Matrix-assisted laser desorption/ionization mass spectrometry (MALDI) is a new, very high-performing development for the analysis of biomolecules (Karas, M. and Hillenkamp, F. 1988. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal. Chem. 60:2299-2301). An analyte molecule is embedded in a matrix absorbing in the UV. The matrix is evaporated in vacuum by a short laser pulse and the analyte is transported into the gas phase unfragmented. An applied voltage accelerates the ions in a field-free flight tube. Ions are accelerated to varying degrees based on their different masses. Smaller ions reach the detector sooner than larger ions. The time-of-flight is converted to the mass of the ions. Presently, this technology can distinguish molecules with a mass difference of 1 Da in the mass region from 1,000 to 4,000 Da. Due to the natural distribution of isotopes, most biomolecules, however, are approximated within 5 Da. Technically, this mass-spectrometric method can be very suitable for the analysis of biomolecules, but in order to distinguish them, the products that are to be analyzed must lie at least 5 Da apart from one another. Therefore, 600 molecules can be distinguished in this mass region. In the region between 4,000 and 100,000 Da, isotope

resolution is no longer achieved, but this region can also be used. Recently, the application of an infrared (IR) laser coupled with the MALDI analysis of DNA has been described (Berkenkamp, S., Kirpkar, F. and Hillenkamp, F. 1998. Infrared MALDI mass spectrometry of large nucleic acids. *Science*. 281: 260-262). It was possible by means of this combined technique to detect DNA fragments with a size of up to 2,500 bases.

Chemical mismatch cleavage is a method by means of which small differences between two single strands of DNA can be indicated (Cotton, R.G.H., Rodriguez, N.R. and Campbell, R.D. 1988. Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. *Proc. Natl. Acad. Sci. USA*. 85: 4397-4401; Cotton, R.G.H. 1993. Current methods for mutations detection. *Mut. Res.* 285: 125-144; Saleeba, J.A., and Cotton, R.G.H. 1993. Chemical cleavage of mismatch to detect mutations. *Methods in Enzymology*. 217: 286-295; Smooker, P.M. and Cotton, R.G.H. 1993. The use of chemical reagents in the detection of DNA mutations. *Mutations Res.* 288: 65-77). The chemical reactivity of C and T relative to osmium tetroxide and of C relative to hydroxylamine is increased, if these are not paired with their respective complementary bases. The nucleic acid strand is broken at the modified position by subsequent treatment with piperidine.

Another possibility to indicate non-complementary base pairs in heteroduplex DNA consists of the application of enzymes such as MutS, which bind to non-complementary base pairs (Smith, J. and Modrich, P. 1996.

At the present time, a rapid, cost-favorable and automatable method for finding methylated cytosines in genomic DNA is lacking. Such a method, however, is of great interest, since different methylation patterns can be drawn on in a variety of ways for characterizing cell types and thus can be used for diagnosis and classification of diseases (such as, for example, tumors) and this method could also be utilized, for example, for studies of cell differentiation.

The object is resolved according to the invention by a method for the identification of 5-methylcytosine positions in genomic DNA, whereby the following method steps are conducted:

- a) the genomic DNA of a cell, a cell line, a tissue or an individual is chemically treated in such a way that cytosine and 5-methylcytosine react differently and a different base-pairing behavior results for the two products in the duplex,
- b) the same nucleic-acid segment is amplified by means of a polymerase reaction,
- c) the same nucleic-acid segment of at least one other cell, cell line, tissue or individual or any desired reference DNA is treated according to steps a) and b),

- d) heteroduplexes are formed from the at-least two amplified products of steps b) and c),
- e) a detectable labeling is introduced into the heteroduplex by means of a reaction, which is specific to non-complementary base pairs.

According to the invention, it is preferred that for the identification of differences in the cytosine methylation pattern between various cells, cell lines, tissues and individuals, only those positions are applied and indicated, in which the cytosine methylation is variable between different cells, cell lines, tissues or individuals.

It is also preferred that a disulfite (bisulfite, pyrosulfite) is utilized as the reagent for the selective conversion of cytosine to uracil in step a), whereby 5-methylcytosine remains unchanged.

It is also preferred that genomic DNA of several individuals, tissues, cell lines or cells is jointly amplified in step b).

In addition, it is preferred that genomic DNA of several individuals, tissues, cell lines or cells is separately amplified and then jointly treated according to step e).

It is also preferred according to the invention that erroneous base pairings are produced by formation of heteroduplexes from the DNA of different individuals, tissues, cell lines or cells at the positions at which a 5-methylcytosine was localized in the genomic DNA.

It is also preferred that erroneous base pairings occur in step d) at the positions at which 5-methylcytosine was found in the genomic DNA, by formation of heteroduplexes with a completely demethylated reference DNA.

It is also preferred that the DNA at the erroneous base pairings is cleaved enzymatically specifically or sufficiently selectively.

It is preferred that the analysis of size (molecular weights) of the DNA fragments is conducted by means of mass spectrometry.

It is particularly preferred that the fragments are analyzed by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI).

It is also particularly preferred that the fragments are analyzed by means of electrospray ionization mass spectrometry (ESI).

It is particularly preferred that the size of the fragments produced in step e) is adapted to the performance capacity of the mass spectrometer.

It is most particularly preferred that several PCRs of a gene segment are conducted and the primers are set stepwise such that the fragment size to be expected at least in one of these PCRs falls in the mass range that can be detected by means of mass spectrometry.

It is particularly preferred that one of the PCR primers is newly positioned stepwise by the maximally detectable mass range of the mass spectrometer relative to the other primer.

It is preferred according to the invention that in step b) one primer of the PCR is provided with a chemical function, so that the PCR product can be immobilized on a surface.

It is also preferred according to the invention that the PCR product produced in step b) is transferred into different reaction vessels and the surfaces of the reaction vessels are treated chemically in such a way that the PCR product can be bound thereon.

It is also particularly preferred that PCR products of different individuals that are prepared in step c) are transferred into different reaction vessels prepared as described above.

In addition, it is preferred according to the invention that an enzyme is used for step e), which [enzyme] forms a complex with a non-complementary base pair.

It is very particularly preferred that this enzyme is Muts.

In addition, it is preferred that the enzyme bears a label, by means of which a complex can be visualized.

It is also preferred according to the invention that the label is a fluorescence label, a chemiluminescence label, a mass label or a photochemically cleavable mass label.

In addition, it is preferred according to the invention that an amplified DNA sample according to step c) in claim 1, which displays a difference relative to an amplified DNA sample in step b) is compared in a second run of the method itself [with] a [similar] DNA sample according to step b) in claim 1 and with all other DNA samples to be investigated.

It is also preferred according to the invention that a preselection of the gene segments to be investigated in detail by mass spectrometry will be conducted by means of a fluorescence labeling or chemiluminescence labeling of the immobilized DNA strand, the lack of which indicates the presence of methylated cytosines in the investigated genomic DNA segment after conducting steps d) and e) of claim 1 and a washing step.

It is further preferred according to the invention that a preselection of the gene segments to be investigated in detail by mass spectrometry is conducted by means of a more nonspecific variant according to claims 20 to 23.

Another subject of the present invention is a kit for conducting the method according to the invention, comprising DNA of at least two individuals, tissues, cell lines or cells that are as different as possible as well as reagents, in order to indicate the variable methylation positions.

The [kit] according to the invention also comprises completely methylated and/or demethylated DNA and reagents, which are necessary for the detection of methylated cytosines in any DNA sample.

The method according to the inventions serves for the identification of 5-methylcytosine positions in genomic DNA, which can be of the most varied origin. The genomic DNA is first treated chemically in such a way that a difference is produced in the reaction of cytosine bases and of to 5-methylcytosine bases. Possible reagents here include, e.g., disulfite (also denoted bisulfite or pyrosulfite), hydrazine and permanganate. In a preferred variant of the method, the genomic DNA is treated with disulfite in the presence of hydroquinone or hydroquinone derivatives, whereby the cytosine bases are converted to uracil selectively after subsequent alkaline hydrolysis. 5-Methylcytosine remains unchanged under these conditions. After a purification process, which serves for separating the excess disulfite, a specific segment of the pretreated genomic DNA is now amplified in a polymerase reaction. In a preferred variant of the method, the polymerase chain reaction is used here. Then, the same segment of another genomic DNA sample is amplified to the same extent. The two amplified products are combined, whereby heteroduplexes are partially formed. In a preferred variant of the method, this is

produced in such a way that one of the PCR primers bears a function suitable for immobilization and that only one strand of the amplified product of the first sample is immobilized and then a hybridization is performed with the amplified product of the second sample. In another preferred variant, a multiple number of different amplified products of the same nucleic-acid segment are hybridized in this manner with the immobilized single strand of the amplified product of the first sample, which was first distributed in many wells of a microtiter plate. Now one hybridization experiment can be conducted in each well.

After the hybridization, a method is conducted, which leaves behind a detectable label at those positions in which an erroneous base pairing occurs in the heteroduplex. In a preferred variant of the method, this is conducted by chemical mismatch cleavage, which leads to a break of the backbone at the positions where an erroneous base pairing has occurred. The fragments obtained in this way can be analyzed by any method that can indicate the size of DNA fragments. Such a method should ideally permit conclusions on any position in the amplified nucleic-acid segment of the sample, at which an erroneous pairing has occurred in the heteroduplex. Erroneous base pairings in the heteroduplex are present particularly if, in the DNA of one sample, cytosine was present at this position, which was converted to uracil, but in the other sample, 5-methylcytosine was present, which remained unchanged in the chemical pretreatment. The method can be utilized also for the comparison of two or more genomic DNA samples; in this case, the analysis of the fragments supplies only the differences in the methylation pattern between the two samples

in the respective amplified nucleic-acid segment. However, it is also possible to utilize a DNA as a reference which has been completely methylated or demethylated enzymatically at C. In this case, the analysis of the fragments supplies all 5-methylcytosine positions in the respective amplified nucleic-acid segment.

In a particularly preferred variant of the method, mass spectrometry is applied to the analysis of fragments. After a preliminary purification, the fragments can be analyzed in the MALDI mass spectrometer. Alternatively, the solutions can be analyzed by electrospray ionization mass spectrometry (ESI). It may be necessary to investigate the nucleic-acid segment in question in several substeps by newly positioning a primer stepwise in several PCRs, each time depending on the performance capability of the method and the instrument utilized, and thus various amplified products of the substeps result ("primer walking").

In a variant of the method, the erroneous base pairings – alternatively to the analysis of fragments after a backbone cleavage in the heteroduples – may also be detected by means of an enzyme, which forms a complex with a non-complementary base pair. In a preferred variant, this enzyme is MutS, which bears a label, e.g., a fluorescence, chemiluminescence or mass label.

In another variant of the method, the presence of erroneous base pairings, i.e., in this case also the presence of relevant information in the amplified nucleic-acid segment, is detected by a fluorescence or chemiluminescence labeling. In a preferred variant of the method, an

Heteroduplexes are formed with the amplified product of sample 2, and these are subjected to a chemical mismatch cleavage. If a backbone cleavage occurs at the immobilized strand, then the fluorescence label disappears after a denaturing washing step, and if the strand is not cleaved, then the label remains. Only the amplified products that have been cleaved are subsequently investigated in more detail by mass spectrometry.

Example 1

The genomic DNA to be investigated that derives from a cell line, or as much as possible from only one cell, is divided into two reaction vessels and one-half of this is either completely methylated or demethylated enzymatically at the cytosine. The enzyme is thermally inactivated and then both parts are again combined and treated with disulfite and then alkali. After a purification, amplification is conducted by means of PCR.

The chemical mismatch cleavage that is specific for the C mismatch and that is now conducted leads to a cleavage at the positions of a corresponding heteroduplex, at which an originally methylated C was found, if a complete demethylation of one-half of the genomic sample was conducted. On the other hand, a cleavage occurs at all originally non-methylated positions, if a complete

methylation of one-half of the genomic sample was previously conducted. For reliability, both methylation as well as demethylation may be conducted as a reference, but in this case, these procedures must be performed separately in two PCRs.

Variant 1: The above method is conducted in such a way that a primer is introduced in the PCR, which is functionalized such that a simple and specific immobilization is made possible after PCR. The immobilization is conducted onto beads or onto the surface of a microtiter plate. This permits the simple separation of components of the polymerase and mismatch cleavage reactions. After the chemical mismatch cleavage reaction, the duplex is thermally denatured and the solution is pipetted off. The DNA fragments from this solution are introduced onto a reversed-phase material and purified.

In the mass spectrometer, the fragments produce a “ladder” of peaks from which the methylated positions can be inferred. Theoretically, two peaks per CpG always occur at CpG positions on the basis of the symmetrical methylation; these peaks originate from the sense and anti-sense strands.

Variant 2: The reactions are conducted in solution and a purification is conducted after the individual reaction steps, if necessary, each time by means of a reversed-phase material.

Variant 3: Several individuals or cell types are parallelly investigated. A reference DNA is completely demethylated and then treated with disulfite. It is amplified by means of PCR after purification. A primer is again used, which bears a function suitable for the immobilization. The solution is distributed onto

the wells of a microtiter plate and immobilized. Then a hybridization is conducted against the PCR products from the samples also treated with disulfite, each time, one [product] per well (see also the described example with 97 individuals).

Variant 4: If the mass spectrometer cannot cover the [entire] measurement range, which would be necessary for the analysis of the total PCR product to determine methylations, the region of interest can also be found stepwise by conducting several PCRs and each time placing one of the primers closer to the other by the respective measurement range of the mass spectrometer. Thus, for example, only that region is detected, which lies between the primer to be shifted of the PCR in question and the next PCR. The method can be combined with the other variants.

Example 2

Method for finding positions with variable cytosine methylation

DNA of various individuals or cell lines is pooled and a treatment with disulfite is conducted as described above. After alkaline hydrolysis of the bisulfite adducts and purification of the product DNA, the latter is amplified by means of PCR. It is then purified again and after several minutes of reannealing at 25°C with OsO₄, the PCR product is cleaved at the positions with a C mismatch (chemical mismatch cleavage). A C → A mismatch then always occurs, if a methylated cytosine has been present only in several individuals prior

to the bisulfite treatment. In this process, possible SNPs (single nucleotide polymorphisms), as it were, also lead to the cleavage of the DNA. The latter must be distinguished from the methylated positions to be found, which is assured by employing the above-described method for finding all methylated cytosines.

The DNA product is now investigated by mass spectrometry, as described above. If the initially generated PCR product is longer than can be detected with the currently available technology relative to mass spectrometry, then it is possible that the fragments produced by the chemical mismatch cleavage cannot be detected. In order to get around this, several PCRs can be conducted iteratively, i.e., one primer will always be kept constant, while the other primer will be positioned closer to the other primer continually in several steps, each time by the detection limit of the mass spectrometer (primer walking).

Example 3

Method with 97 individuals

A genomic segment of an individual (reference individual) is treated with disulfite and in this way, the cytosines are converted into uracils after subsequent alkaline hydrolysis of the bisulfite adduct. The methylcytosines remain unaffected in this reaction sequence. The product is purified and amplified by means of PCR. One of the PCR primers is provided on the 5' end with a chemical modification, which serves for immobilization. The product of this PCR is placed in the 96 wells of a microtiter plate and the PCR products are induced

to bind to the surface. Since only one primer is provided with the chemical modification for such binding, only one DNA strand binds to the surface. The plate is washed to eliminate the reagents of the binding chemistry and the complementary strands. In this way, the plate containing the reference DNA piece is prepared. The same genomic segment in each of the 96 other individuals is treated analogously with disulfite and then amplified. Each time two normal unmodified primers of the same sequence as for the reference individual are used for this PCR. The 96 PCR products are placed in the 96 wells of the prepared plate. By heating and slow cooling, the complementary strands of the 96 individuals are hybridized to the reference DNA (formation of the heteroduplex). The 96 individuals and reagents of the previous reactions [are] to be eliminated. An OsO_4 solution is added to each of the 96 wells, incubated, and then a backbone cleavage is induced with piperidine in a heteroduplex with a non-complementary base pair, one base of which is C. This will happen only if a methylcytosine is present instead of a cytosine in one strand of the heteroduplex, i.e. in one of the individuals. In this case, only the cytosine of one individual was converted to a uracil prior to the PCR, whereby a mismatch results in the heteroduplex with the counter-strand of another individual. The assay thus does not directly produce all methylated cytosines of a genomic segment, but only those that are variable between different individuals, tissues, cell lines or individual cells.

The heteroduplex is melted apart by heating and the solution is transferred to a mass spectrometer.

Transfer of the solution to the mass spectrometer

Example 5

The genomic DNA to be investigated is immobilized on beads or an appropriately coated microtiter plate after the bisulfite reaction with subsequent PCR amplification as described above, in which one of the primers again bears a function that can serve for the subsequent immobilization. Completely demethylated DNA, treated like the sample DNA, is used as reference DNA and forms a heteroduplex with the immobilized sample DNA. Then an individual fluorescence-labeled base is attached enzymatically, for example, with terminal transferase to the 3' ends of the product. The subsequently conducted

“chemical mismatch cleavage” reaction in the case where a C/A mismatch is found in the product, leads to a cleavage of the immobilized strand, so that all fluorescence labelings are removed in the subsequent washing step after the thermal dehybridization. Thus a methylation was present within the amplified product, so that fluorescence no longer occurs in the microtiter plate or on the bead. The fluorescence only remains, if no mismatch is present, and thus no 5-methylcytosines are present in the gene segment in question. In the method, it must be considered that, e.g., SNPs may yield a false positive signal.

Accordingly, this method may be utilized also for simple, fluorescence-based detection of 5-methylcytosines in small gene segments, e.g. promoters. However, information may only be found of whether or not methylations are present in the region in question, but not how many and at which positions. Of course, this is compensated by a relatively small experimental expenditure and a good capability for conducting parallel experiments.

Then, analogously to one of the above-described examples, the precise position of methylcytosines can be determined by mass spectrometry in the gene segments classified as relevant.

Example 6

Preselection of heteroduplexes with mismatches

The heteroduplexes immobilized in one microtiter plate are first combined with a solution of MutS, to which a fluorescent dye is bound. Only the vessels, in which MutS has attached to erroneous base pairing positions, which is indicated

by the fact that the fluorescence can still be detected after several washing steps, are subsequently subjected to the chemical mismatch cleavage and analyzed in the mass spectrometer. In this way, time in the mass spectrometer and costs for purification are spared, since analysis of samples without detectable epigenetic information is avoided.

Patent Claims

1. Method for the identification of 5-methylcytosine positions in genomic DNA is characterized by the fact that the following method steps are conducted:

- a) the genomic DNA of a cell, a cell line, a tissue or an individual is chemically treated in such a way that cytosine and 5-methylcytosine react differently and a different base pairing behavior of the two products results in the duplex,
- b) the same nucleic-acid segment is amplified by means of a polymerase reaction,
- c) the same nucleic-acid segment of at least one other cell, cell line, tissue or individual or any reference DNA is treated according to steps a) and b),
- d) heteroduplexes are formed from the at-least two amplified products of steps b) and c),
- e) a detectable label is introduced into the heteroduplex by means of a reaction, which is specific for non-complementary base pairs.

2. Method according to claim 1, further characterized in that only positions are used and indicated in which the cytosine methylation is variable between different cells, cell lines, tissues or individuals, for identification of differences in cytosine methylation patterns between different cells, cell lines, tissues and individuals.

3. Method according to claims 1 to 2, further characterized in that disulfite (bisulfite, pyrosulfite) is utilized as the reagent for selective conversion of

cytosine to uracil, whereby 5-methylcytosine remains unchanged, in step a) according to claim 1.

4. Method according to one of claims 1 to 3, further characterized in that genomic DNA of several individuals, tissues, cell lines or cells is amplified jointly in step b) of claim 1.

5. Method according to one of claims 1 to 3, further characterized in that genomic DNA of several individuals, tissues, cell lines or cells is amplified separately and then treated jointly according to step e) of claim 1.

6. Method according to one of claims 1 to 5, further characterized in that by formation of heteroduplexes from the DNA of different individuals, tissues, cell lines or cells, erroneous base pairings are produced at the positions at which a 5-methylcytosine was localized in the genomic DNA.

7. Method according to claim 1, further characterized in that in step d), by formation of heteroduplexes with a completely methylated reference DNA, erroneous base pairings occur at the positions at which cytosine was found in the genomic DNA.

8. Method according to claim 1, further characterized in that in step d), by formation of heteroduplexes with a completely demethylated reference DNA,

erroneous base pairings occur at those positions at which 5-methylcytosine was found in the genomic DNA.

9. Method according to one of claims 6 to 8, further characterized in that the erroneous base pairings by means of "chemical mismatch cleavage" (chemical modification at non-complementary positions) lead to a specific or sufficiently selective backbone cleavage at these positions.

10. Method according to one of claims 6 to 8, further characterized in that the DNA is cleaved enzymatically specifically or sufficiently selectively at the erroneous base pairings.

11. Method according to one of claims 1 to 10, further characterized in that DNA fragments are obtained in step e) according to claim 1, whose size infers the cleavage positions and thus the position of methylcytosines and/or the methylation positions that differ between different individuals, tissues, cell lines or cells.

12. Method according to claim 11, further characterized in that the analysis of size (molecular weight) of the DNA fragments is conducted by means of mass spectrometry.

13. Method according to claim 12, further characterized in that the fragments are analyzed by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI).

14. Method according to claim 12, further characterized in that the fragments are analyzed by means of electrospray ionization mass spectrometry (ESI).

15. Method according to claims 13 or 14, further characterized in that the size of the fragments produced in step e) according to claim 1 is adapted to the performance capacity of the mass spectrometer.

16. Method according to claim 15, further characterized in that several PCRs of a gene segment are introduced and the primers are set stepwise newly each time so that the fragment size to be expected each time at least in one of these PCRs falls in the mass range detectable by means of mass spectrometry.

17. Method according to claim 16, further characterized in that one of the PCR primers is positioned newly stepwise by the maximally detectable mass range of the mass spectrometer, relative to the other primer.

18. Method according to one of claims 1 or 2, further characterized in that in step b) one primer of the PCR is provided with a chemical function, so that the PCR product can be immobilized on a surface.

19. Method according to one of claims 1 or 2, further characterized in that the PCR product produced in step b) is transferred to different reaction vessels and the surfaces of the reaction vessels are chemically treated such that the PCR product can be bound thereon.

20. Method according to one of claims 1 or 2, further characterized in that PCR products of different individuals that are produced in step c) are transferred into different reaction vessels prepared according to claim 19.

21. Method according to one of claims 1 or 2, further characterized in that an enzyme which forms a complex with a non-complementary base pair is used for step e).

22. Method according to claim 21, further characterized in that this enzyme is MutS.

23. Method according to claim 21, further characterized in that the enzyme bears a label, by which a complex can be displayed.

24. Method according to claim 21, further characterized in that the label is a fluorescence label, a chemiluminescence label, a mass label or a photochemically cleavable mass label.

26. Method according to one of claims 1 to 25, further characterized in that a preselection of gene segments to be investigated in detail by the mass spectrometer is conducted by means of fluorescence labeling or chemiluminescence labeling of the immobilized DNA strand, the lack of which, after conducting steps d) and e) of claim 1 and a washing step, indicates the presence of methylated cytosines in the investigated genomic DNA segment.

28. Kit for conducting a method according to claim 1, comprising DNA of at least two individuals, tissues, cell lines or cells that are as different as possible, along with reagents, in order to indicate the variable methylation positions.

29. Kit for conducting the method according to claim 1, comprising completely methylated and/or demethylated DNA and reagents, which are necessary for the detection of methylated cytosines in any DNA sample.

090533 08291
T0E280"EE95860

Abstract

A method is described for the identification of 5-methylcytosine positions in genomic DNA, which is characterized by the fact that the following method steps are conducted:

- a) the genomic DNA of a cell, a cell line, a tissue, or an individual is chemically treated in such a way that cytosine and 5-methylcytosine react differently and a different base pairing behavior of the two products is produced in the duplex,
- b) the same nucleic-acid segment is amplified by means of a polymerase reaction,
- c) the same nucleic-acid segment of at least one other cell, cell line, tissue or individual or any reference DNA is treated according to items a) and b),
- d) heteroduplexes are formed from the at-least two amplified products of items b) and c),
- e) a label that can be displayed is introduced into the heteroduplex by a reaction, which is specific for non-complementary base pairs.

FOR EMISSION

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled, **METHOD FOR THE IDENTIFICATION OF CYTOSINE METHYLATION PATTERNS IN GENOMIC DNA**, the specification of which: (check one)

☐ is attached hereto.

☒ was filed as PCT International Application No. PCT/DE99/03747 on November 19, 1999 and has been assigned United States Serial No. 09/856,333.

☐ was filed on _____; and assigned Serial No.: _____.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)		Priority Claimed
<u>198 53 398.5</u>	<u>GERMANY</u>	<u>November 19, 1998</u>
(number)	(country)	(day/month/year filed)
_____	_____	_____
(number)	(country)	(day/month/year filed)

[X] yes [] no
[] yes [] no

I hereby claim the benefit under Title 35, United States Code, 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER

FILING DATE:

81669

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations 1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u>(application number)</u>	<u>(filing date)</u>	<u>(Status - patented, pending, abandoned)</u>
<u>(application number)</u>	<u>(filing date)</u>	<u>(Status - patented, pending, abandoned)</u>
<u>(application number)</u>	<u>(filing date)</u>	<u>(Status - patented, pending, abandoned)</u>
<u>(application number)</u>	<u>(filing date)</u>	<u>(Status - patented, pending, abandoned)</u>

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Irving M. Kriegsmann, Esq., Reg. No. 22,733; Edward M. Kriegsmann, Esq., Reg. No. 33,529; and Daniel S. Kriegsmann, Esq., Reg. No. 40,057.

Please send all correspondence to:

KRIEGSMAN & KRIEGSMAN
665 Franklin Street
Framingham, MA 01702
(508) 879-3500

I hereby declare that all statements made herein of my own knowledge are true and that any statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Inventor (given name, family name): KATHRIN BERLIN
Residence: Marienkäferweg 4, D-14532 Stahnsdorf, Germany **DEX**
Post Office Address: Marienkäferweg 4, D-14532 Stahnsdorf, Germany
Citizenship: GERMANY

Inventor's signature: Dr. K. Berlin Date: 8.8.01